| Titre |
Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study |
| Protocole ID |
FORUM |
| ClinicalTrials.gov ID |
NCT02670564 |
| Type(s) de cancer |
Pédiatrique divers |
| Phase |
Phase IV |
| Type étude |
Génétique |
| Institution |
CENTRE HOSPITALIER UNIVERSITAIRE SAINTE-JUSTINE
|
| Ville |
Montréal |
| Investigateur(trice) principal(e) |
Dr Michel Duval
|
| Coordonnateur(trice) |
Anthony Gallego
514-345-4931 poste 3627
|
| Statut |
![]() Fermé |
| Critètes d'éligibilité |
-
age at time of screening less than 18 years old
-
Patients with ALL (except for patients with B-ALL)
-
indication for allogeneic HSCT
-
complete remission (CR) before HSCT
-
written consent of the parents (legal guardian) and, if necessary, the minor patient via "Informed Consent Form"
-
no pregnancy
-
no secondary malignancy
-
no previous HSCT
-
HSCT is performed in a study participating centre
|
| Critètes d'exclusion |
-
Non Hodgkin-Lymphoma
-
ALL with extramedullary involvement with indication for TBI
-
CNS involvement at the timepoint of screening
-
Trisomy 21
-
The whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian
-
No consent is given for saving and propagation of anonymous medical data for study reasons
-
Severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders)
-
Karnofsky / Lansky score < 50%
-
Subjects unwilling or unable to comply with the study procedures
|
Groupe d'étude en oncologie du Québec